All In Biotech

Drug Trial Radar · NCT07232602

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04-Substudy 04D

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Feb 9, 2026

Primary completion

Jul 8, 2031

Study completion Jul 8, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat people with urothelial cancer (UC) that is locally advanced or metastatic. The standard treatment for locally advanced or metastatic UC is enfortumab vedotin (EV) given with pembrolizumab. The goals of this study are to learn about: * The safety of the study treatment when given with standard treatment and if people tolerate it * The number of people who have the cancer respond (cancer gets smaller or goes away) with the new study treatment when given with standard treatment.

Conditions

  • Bladder Cancer

Interventions

  • MK-3120Drug

    Administered via intravenous (IV) infusion on day 1 and day 8 of each 3-week cycle

  • EVDrug

    Administered via IV infusion on day 1 and day 8 of each 3-week cycle

  • PembrolizumabBiological

    Administered via IV infusion on day 1 of each 3-week cycle

  • Rescue MedicationDrug

    Participants receive rescue medication at the investigator's discretion, per approved product label. Recommended rescue medication is Granulocyte Colony-Stimulating Factor (G-CSF).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 27 months
  2. Number of Participants Who Experience a Dose Limiting Toxicity (DLT)Time frame: Up to approximately 21 days
  3. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 24 months
  4. Objective Response Rate (ORR) as Assessed by InvestigatorTime frame: Up to approximately 58 months

Locations

17 sites in 8 countries. Site status is shown where the registry gives one.

  • UCSF Medical Center at Mission Bay ( Site 5044)

    San Francisco, California · Recruiting

  • University of Chicago Medical Center ( Site 5037)

    Chicago, Illinois · Recruiting

  • Memorial Sloan Kettering Cancer Center ( Site 5031)

    New York, New York · Recruiting

  • Cleveland Clinic Taussig Cancer ( Site 5036)

    Cleveland, Ohio · Recruiting

  • Huntsman Cancer Institute ( Site 5041)

    Salt Lake City, Utah · Recruiting

  • Fundación Arturo López Pérez ( Site 5151)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • CHU de Bordeaux Hop St ANDRE ( Site 5607)

    Bordeaux, Gironde, France · Recruiting

  • Rambam Health Care Campus ( Site 5501)

    Haifa, Israel · Recruiting

  • Rabin Medical Center ( Site 5504)

    Petah Tikva, Israel · Recruiting

  • Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 5302)

    Amsterdam, North Holland, Netherlands · Recruiting

  • Erasmus MC ( Site 5303)

    Rotterdam, South Holland, Netherlands · Recruiting

  • Severance Hospital, Yonsei University Health System ( Site 5903)

    Seoul, South Korea · Recruiting

  • Asan Medical Center ( Site 5901)

    Seoul, South Korea · Recruiting

  • Samsung Medical Center ( Site 5902)

    Seoul, South Korea · Recruiting

  • Hospital Universitari Vall de Hebron ( Site 5767)

    Barcelona, Spain · Recruiting

  • Hospital Clinico San Carlos ( Site 5765)

    Madrid, Spain · Recruiting

  • St Bartholomew s Hospital ( Site 5206)

    London, London, City of, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.